Padsevonil

Generic Name: Padsevonil

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄ClF_₅N_₄O_₂S

CAS Number: 1294000-61-5

Unique Ingredient Identifier: 0R1HN52K0N

Background: Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Phase 1

Terminated

Conditions: Healthy Study Participants
Impaired Hepatic Function

Interventions: Drug: Padsevonil

First Posted Date: 2019-10-23

Last Posted Date: 2021-07-28

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 12

Registration Number: NCT04136444

Locations: 🇺🇸
Up0056 004, Orlando, Florida, United States

A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

Phase 1

Terminated

Conditions: Healthy Female Participants

Interventions: Drug: Padsevonil
Drug: Microgynon 30®

First Posted Date: 2019-10-18

Last Posted Date: 2021-06-24

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 14

Registration Number: NCT04131517

Locations: 🇬🇧
Up0035 001, London, United Kingdom

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

Phase 1

Terminated

Conditions: Healthy Study Participants

Interventions: Drug: Placebo
Drug: Moxifloxacin
Drug: Padsevonil

First Posted Date: 2019-10-15

Last Posted Date: 2021-06-18

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 54

Registration Number: NCT04126343

Locations: 🇬🇧
Up0050 001, London, United Kingdom

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Phase 1

Completed

Conditions: Healthy Japanese Participants

Interventions: Drug: Padsevonil

First Posted Date: 2019-08-30

Last Posted Date: 2021-07-08

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 39

Registration Number: NCT04075409

Locations: 🇯🇵
Up0083 001, Tokyo, Japan

A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: Placebo (PSL)
Drug: Padsevonil

First Posted Date: 2019-07-31

Last Posted Date: 2021-06-18

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 40

Registration Number: NCT04039919

Locations: 🇳🇱
Up0071 001, Leiden, Netherlands

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

Phase 1

Completed

Conditions: Elderly Study Participants
Adult Study Participants

Interventions: Drug: Padsevonil

First Posted Date: 2019-07-09

Last Posted Date: 2021-06-30

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 28

Registration Number: NCT04013191

Locations: 🇺🇸
Up0053 001, San Antonio, Texas, United States

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Phase 3

Terminated

Conditions: Drug-Resistant Epilepsy
Focal-Onset Seizures

Interventions: Drug: Padsevonil
Drug: Placebo

First Posted Date: 2018-11-14

Last Posted Date: 2022-12-21

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 232

Registration Number: NCT03739840

Locations: 🇧🇬
Ep0092 150, Blagoevgrad, Bulgaria
🇭🇷
Ep0092 128, Zagreb, Croatia
🇪🇪
Ep0092 276, Tallinn, Estonia

and more 138 locations

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Padsevonil
Drug: Levetiracetam
Drug: Oxcarbazepine
Drug: Lamotrigine
Drug: Brivaracetam

First Posted Date: 2018-10-03

Last Posted Date: 2020-06-04

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 31

Registration Number: NCT03695094

Locations: 🇳🇱
Up0070 401, Leiden, Netherlands
🇧🇬
Up0070 101, Sofia, Bulgaria

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Phase 2

Completed

Conditions: Focal-Onset Seizures
Drug-resistant Epilepsy

Interventions: Drug: Padsevonil
Other: Placebo

First Posted Date: 2017-12-14

Last Posted Date: 2023-12-19

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 411

Registration Number: NCT03373383

Locations: 🇺🇸
Ep0091 830, Dallas, Texas, United States
🇺🇸
Ep0091 801, San Francisco, California, United States
🇺🇸
Ep0091 823, Orlando, Florida, United States

and more 145 locations

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Phase 2

Terminated

Conditions: Drug-Resistant Epilepsy
Focal-Onset Seizures

Interventions: Drug: Padsevonil

First Posted Date: 2017-12-12

Last Posted Date: 2021-12-29

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 406

Registration Number: NCT03370120

Locations: 🇺🇸
Ep0093 645, Golden Valley, Minnesota, United States
🇺🇸
Ep0093 806, Hackensack, New Jersey, United States
🇺🇸
Ep0093 802, Philadelphia, Pennsylvania, United States

and more 153 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy